Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs

TIPRANKS05-13

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DFTX stock, giving a Buy rating today. Patrick Trucchio has given h...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment